Eliciting preferences for drug treatment of lower urinary tract symptoms associated with benign prostatic hyperplasia.
about
Effects of pumpkin seed oil and saw palmetto oil in Korean men with symptomatic benign prostatic hyperplasiaSurgical treatments for men with benign prostatic enlargement: cost effectiveness study.Measuring the improvement in health-related quality of life using King's health questionnaire in non-obese and obese patients with lower urinary tract symptoms after alpha-adrenergic medication: a preliminary studyPatient-reported outcomes in men with lower urinary tract symptoms (LUTS) due to benign prostatic hyperplasia (BPH) treated with intraprostatic OnabotulinumtoxinA: 3-month results of a prospective single-armed cohort study.Patient preferences and willingness to pay for innovations in intermittent self-catheters.A descriptive review on methods to prioritize outcomes in a health care context.Management of experimental benign prostatic hyperplasia in rats using a food-based therapy containing Telfairia occidentalis seedsEfficacy and safety of tamsulosin for treating lower urinary tract symptoms associated with benign prostatic hyperplasia: a multicenter, randomized, controlled, open-label non-inferiority study.Dutasteride: an evidence-based review of its clinical impact in the treatment of benign prostatic hyperplasia.Treatment of lower urinary tract symptoms suggestive of benign prostatic hyperplasia: the cardiovascular system.Understanding patient and physician perceptions of benign prostatic hyperplasia in Europe: The Prostate Research on Behaviour and Education (PROBE) SurveyPatients' preferences for osteoporosis drug treatment: a discrete choice experiment.Men's preferences for the treatment of lower urinary tract symptoms associated with benign prostatic hyperplasia: a discrete choice experiment.Patient preferences for first-line oral treatment for mild-to-moderate ulcerative colitis: a discrete-choice experiment.Burden of male lower urinary tract symptoms (LUTS) suggestive of benign prostatic hyperplasia (BPH) - focus on the UK.Effect of dutasteride on clinical progression of benign prostatic hyperplasia in asymptomatic men with enlarged prostate: a post hoc analysis of the REDUCE study.Does one size fit all? Investigating heterogeneity in men's preferences for benign prostatic hyperplasia treatment using mixed logit analysis.Actual medical management of lower urinary tract symptoms related to benign prostatic hyperplasia: temporal trends of prescription and hospitalization rates over 5 years in a large population of Italian men.Inhibition of the experimental induction of benign prostatic hyperplasia: a possible role for fluted pumpkin (Telfairia occidentalis Hook f.) seeds.OnabotulinumtoxinA injection therapy in men with LUTS due to primary bladder-neck dysfunction: objective and patient-reported outcomes.The Best of Both Worlds: An Example Mixed Methods Approach to Understand Men's Preferences for the Treatment of Lower Urinary Tract Symptoms.Patient's behavior and attitudes toward the management of benign prostatic hyperplasia among patients with the risk of disease progression: prospective study by "Prostate and Expectations of Treatment Epidemiology Research (PETER) study group".A survey conducted on patients' and urologists' perceptions of benign prostatic hyperplasia
P2860
Q24642371-DED16650-CF23-4CE5-B407-73960B57AF71Q33431091-FBB22297-7253-4640-A4D0-B311D1100ACBQ34020219-FE3FA42B-F6CC-408D-9F72-64A242E65824Q34639437-B99D37D2-6E2E-4048-97FE-DF9E9BB62097Q35173324-A292DFD1-D712-40C7-926B-68645E84DE46Q35231568-CE7E2556-474D-4823-8A6C-1FF448DB3405Q35556690-B62B274A-8587-4C8C-BB2F-A1A91D7DB63BQ35851994-91F4BEAF-4DC1-43CD-9466-AD4349F53108Q35876383-1D3A5D23-7E27-409D-91BC-F9BC2B9624D9Q36116539-8CB87768-8893-417D-A5D5-A70EEEF5C551Q36499690-B97DCBEA-1960-43E0-AF17-889B20B7410DQ36738207-E782C73E-6FEF-455B-BBFA-6367DA1A04FEQ37446463-DFCDD33F-96E6-442C-9551-9D771A4848CFQ37955245-61A83A87-121E-4450-86AB-6E72A7568A73Q38198262-BAC87DA2-75C5-4EBE-801A-E111EA5320B1Q39844699-D44FC8D9-91B4-4547-8056-699AEC30F949Q42632921-A2D3931A-B615-4946-B3C1-0FFB1E3F407CQ45785775-88FE84BE-1CB0-4703-B735-B0CFF255B427Q46892909-F13BC8F4-4347-4841-B3A5-AC80DA289553Q47978895-597B8D4F-EBE4-44EF-9BF0-2FD3E21CFCF6Q48204722-59D98BA5-4FF3-4685-AA99-CFE60BFFFE7FQ53080580-760DAC3E-3107-4C26-9167-96625C1D819CQ57226956-E82254D1-64C6-4F95-B13B-77F070FB6B8E
P2860
Eliciting preferences for drug treatment of lower urinary tract symptoms associated with benign prostatic hyperplasia.
description
2004 nî lūn-bûn
@nan
2004年の論文
@ja
2004年学术文章
@wuu
2004年学术文章
@zh
2004年学术文章
@zh-cn
2004年学术文章
@zh-hans
2004年学术文章
@zh-my
2004年学术文章
@zh-sg
2004年學術文章
@yue
2004年學術文章
@zh-hant
name
Eliciting preferences for drug ...... benign prostatic hyperplasia.
@en
Eliciting preferences for drug ...... benign prostatic hyperplasia.
@nl
type
label
Eliciting preferences for drug ...... benign prostatic hyperplasia.
@en
Eliciting preferences for drug ...... benign prostatic hyperplasia.
@nl
prefLabel
Eliciting preferences for drug ...... benign prostatic hyperplasia.
@en
Eliciting preferences for drug ...... benign prostatic hyperplasia.
@nl
P2093
P1476
Eliciting preferences for drug ...... benign prostatic hyperplasia.
@en
P2093
P304
P356
10.1097/01.JU.0000140957.31325.7F
P407
P433
P577
2004-12-01T00:00:00Z